With opioid utilization decreasing, what concerns do other pain therapies pose?
With opioid utilization decreasing, what concerns do other pain therapies pose?
According to the CWCI, reduced opioid utilization from 2010-2017 saved $6.5 billion in California comp costs.
The guideline covers a wide range of relevant topics, including pain, dosing, dangerous co-prescribing, comorbidities, and more.
The Society of Actuaries published a report that claims the economic burden of the opioid epidemic was $631 billion from 2015-2018.
NKTR-181 (loxicodegol) was to receive an approval decision by August 29th, but a reevaluation of opioid policy has resulted in a delay.
An Oklahoma judge found the drug maker to be partially responsible for the harm of the opioid epidemic.
While many states report fewer opioid prescriptions, MME levels vary more significantly by state.
Generic versions of Ultram (tramadol hydrochloride) tablets and Dyloject (diclofenac sodium) injections have been approved by the FDA.
While the utilization of opioids and other problematic drugs decreased, similar drops were seen in states without closed formularies.
Orphengesic Forte has received a decision date of August 14, 2019.
